Recently, numerous studies have confirmed that systemic anti-tumor immunity is augmented following radiotherapy combined with ICB therapy targeting PD-1/PD-L1 in preclinical models of melanoma, breast cancer, lung cancer and colon cancer. This evidence concerns the gene CD274 and malignant colon neoplasm.